ZA9610405B - New crystal modification of cdch a process for its preparation and pharmaceutical formulations comprising this modification - Google Patents

New crystal modification of cdch a process for its preparation and pharmaceutical formulations comprising this modification

Info

Publication number
ZA9610405B
ZA9610405B ZA9610405A ZA9610405A ZA9610405B ZA 9610405 B ZA9610405 B ZA 9610405B ZA 9610405 A ZA9610405 A ZA 9610405A ZA 9610405 A ZA9610405 A ZA 9610405A ZA 9610405 B ZA9610405 B ZA 9610405B
Authority
ZA
South Africa
Prior art keywords
modification
cdch
preparation
pharmaceutical formulations
new crystal
Prior art date
Application number
ZA9610405A
Other languages
English (en)
Inventor
Alfons Grunenberg
Patrick Bosche
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9610405(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA9610405B publication Critical patent/ZA9610405B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9610405A 1995-12-12 1996-12-11 New crystal modification of cdch a process for its preparation and pharmaceutical formulations comprising this modification ZA9610405B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
ZA9610405B true ZA9610405B (en) 1997-06-23

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610405A ZA9610405B (en) 1995-12-12 1996-12-11 New crystal modification of cdch a process for its preparation and pharmaceutical formulations comprising this modification

Country Status (42)

Country Link
US (1) US5849752A (ja)
EP (1) EP0780390B1 (ja)
JP (1) JP4104687B2 (ja)
KR (1) KR100525146B1 (ja)
CN (1) CN1061348C (ja)
AR (1) AR005009A1 (ja)
AT (1) ATE221531T1 (ja)
AU (1) AU708006B2 (ja)
BG (1) BG62258B1 (ja)
BR (1) BR9605968A (ja)
CA (1) CA2192418C (ja)
CO (1) CO4480105A1 (ja)
CU (1) CU22774A3 (ja)
CZ (1) CZ288657B6 (ja)
DE (2) DE19546249A1 (ja)
DK (1) DK0780390T3 (ja)
EE (1) EE03474B1 (ja)
ES (1) ES2179910T3 (ja)
HR (1) HRP960558B1 (ja)
HU (1) HU226521B1 (ja)
ID (1) ID22625A (ja)
IL (1) IL119795A (ja)
IN (1) IN185805B (ja)
MA (1) MA24342A1 (ja)
MY (1) MY117492A (ja)
NL (1) NL300109I1 (ja)
NO (1) NO306725B1 (ja)
NZ (1) NZ299905A (ja)
PL (1) PL184885B1 (ja)
PT (1) PT780390E (ja)
RO (1) RO119782B1 (ja)
RU (1) RU2162468C2 (ja)
SA (1) SA96170492B1 (ja)
SG (1) SG47201A1 (ja)
SI (1) SI0780390T1 (ja)
SK (1) SK282805B6 (ja)
SV (1) SV1996000109A (ja)
TR (1) TR199600970A2 (ja)
TW (1) TW411340B (ja)
UA (1) UA35638C2 (ja)
YU (1) YU49485B (ja)
ZA (1) ZA9610405B (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU731693B2 (en) * 1997-09-25 2001-04-05 Bayer Intellectual Property Gmbh Drug formulation having controlled release of active compound
DE19751948A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
TR200101310T2 (tr) * 1998-11-10 2001-10-22 Bayer Aktiengesellschaft Farmasötik moksifloksasin preparatı.
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) * 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
WO2004039804A1 (en) * 2002-10-31 2004-05-13 Ranbaxy Laboratories Limited Amorphous moxifloxacin hydrochloride
DE602004022646D1 (de) * 2003-04-09 2009-10-01 Reddys Lab Ltd Dr Kristalline form iii von wasserfreiem moxifloxacin-hydrochlorid und ein verfahren zu seiner herstellung
EP1651630A1 (en) * 2003-08-05 2006-05-03 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
EP1685130B1 (en) * 2003-11-20 2008-12-10 CHEMI S.p.A. Polymorphs of 1-cyclopropyl-7-([s,s] - 2,8-diazadicyclo [4.3.0] non-8-yl) -6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
SI2032521T1 (sl) 2006-06-27 2010-02-26 Sandoz Ag Nov postopek za pripravo soli
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
NZ576929A (en) * 2006-11-13 2012-07-27 Cipla Ltd Crystalline anhydrous form C of moxifloxacin hydrochloride
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
WO2010041100A1 (en) * 2008-10-09 2010-04-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
WO2010052726A1 (en) * 2008-11-06 2010-05-14 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
EP2364141B2 (de) 2008-12-08 2017-08-02 ratiopharm GmbH Kompaktiertes moxifloxacin
CA2762022A1 (en) 2009-05-15 2010-11-18 Redx Pharma Limited Redox drug derivatives
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
US9388178B2 (en) 2012-12-04 2016-07-12 Mankind Research Centre Process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
NO871333L (no) * 1986-03-31 1987-10-01 Sankyo Co Kinolin-3-karboksylsyrederivater, fremgangsmaate til fremstilling og anvendelse derav.
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
TW209865B (ja) 1992-01-10 1993-07-21 Bayer Ag
ATE207479T1 (de) * 1992-01-31 2001-11-15 Chugai Pharmaceutical Co Ltd Kristalle von derivaten von chinozon carbonsäure- hydraten
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
CA2112165C (en) * 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
ATE170400T1 (de) * 1994-04-07 1998-09-15 Pfizer Verwendung von trovafloxacin oder dessen derivaten zur herstellung eines arzneimittels zur behandlung von h.pylori infektionen

Also Published As

Publication number Publication date
KR100525146B1 (ko) 2006-01-27
DK0780390T3 (da) 2002-11-11
IL119795A0 (en) 1997-03-18
EP0780390A1 (de) 1997-06-25
BG101043A (en) 1998-04-30
TR199600970A2 (tr) 1997-06-21
HUP9603428A2 (en) 1997-08-28
RU2162468C2 (ru) 2001-01-27
MY117492A (en) 2004-07-31
HRP960558A2 (en) 1998-02-28
JPH09169757A (ja) 1997-06-30
CO4480105A1 (es) 1997-07-09
ATE221531T1 (de) 2002-08-15
BR9605968A (pt) 1998-08-18
NZ299905A (en) 1998-09-24
SI0780390T1 (en) 2002-10-31
PL184885B1 (pl) 2003-01-31
PL317415A1 (en) 1997-06-23
EP0780390B1 (de) 2002-07-31
DE59609501D1 (de) 2002-09-05
HUP9603428A3 (en) 1997-10-28
JP4104687B2 (ja) 2008-06-18
ID22625A (id) 1999-12-02
NO965298D0 (no) 1996-12-11
YU65096A (sh) 1998-12-23
BG62258B1 (bg) 1999-06-30
PT780390E (pt) 2002-11-29
ES2179910T3 (es) 2003-02-01
CZ288657B6 (cs) 2001-08-15
KR970042550A (ko) 1997-07-24
AU708006B2 (en) 1999-07-29
MX9606325A (es) 1997-10-31
RO119782B1 (ro) 2005-03-30
MA24342A1 (fr) 1998-07-01
SK159196A3 (en) 1997-10-08
HU226521B1 (en) 2009-03-30
TW411340B (en) 2000-11-11
CA2192418C (en) 2001-06-12
AU7421696A (en) 1997-06-19
SV1996000109A (es) 1997-10-23
NO306725B1 (no) 1999-12-13
SG47201A1 (en) 1998-03-20
CZ364696A3 (en) 1997-07-16
DE19546249A1 (de) 1997-06-19
CA2192418A1 (en) 1997-06-13
US5849752A (en) 1998-12-15
SA96170492B1 (ar) 2006-05-23
HRP960558B1 (en) 2002-04-30
CN1160052A (zh) 1997-09-24
EE9600201A (et) 1997-06-16
CN1061348C (zh) 2001-01-31
SK282805B6 (sk) 2002-12-03
YU49485B (sh) 2006-08-17
IL119795A (en) 1998-12-27
UA35638C2 (uk) 2001-04-16
IN185805B (ja) 2001-05-05
CU22774A3 (es) 2002-07-24
NO965298L (no) 1997-06-13
NL300109I1 (nl) 2003-02-03
EE03474B1 (et) 2001-08-15
AR005009A1 (es) 1999-04-07
HU9603428D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
ZA9610405B (en) New crystal modification of cdch a process for its preparation and pharmaceutical formulations comprising this modification
HUP9603112A2 (en) New pharmaceutical formulation and process for its production
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
ZA962438B (en) Acetamide derivative process for preparing the same and a pharmaceutical composition containing the same
AU6501296A (en) Method and apparatus of enhancing the delivery of a pharmaceutical formulation
AU3967795A (en) Method of sterilizing a pharmaceutical composition
HK1010116A1 (en) Naphthalene derivatives process for the preparation thereof and intermediates therefor and pharmaceutical compositions comprising them
IL124268A (en) Hypocholesterolemic (1-aryl-2-oxo-3-substituted-4-azetidinyl) phenylglucopyranose derivatives and pharmaceutical compositions containing them
CZ129596A3 (en) Oxazolidinone derivative, process of its preparation and pharmaceutical composition containing thereof
IL122705A (en) 2-(4-Susbstituted)-benzylamino-2-methyl-propanamide derivatives their preparation and pharmaceutical compositions containing them
IL114059A0 (en) Phenethanolamine derivatives pharmaceutical compositions containing them process for their preparation and their use
HU903907D0 (en) Process for producing pharmaceutical preparations against endoparasites containing 3-hydroxy-benzothiophene derivative and a part of active substances
IL116771A (en) 9-Substituted 2-(2-n-alkoxyphenyl) purin-6-one compounds their preparation and pharmaceutical compositions containing them
IL124841A (en) Pharmaceutical compositions comprising liposomal prostaglandin a method of preparing such compositions and the use of liposomal prostaglandin for said preparation
IL117495A0 (en) Beta-alanine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
IL115125A0 (en) Pharmaceutical formulations comprising derivatives of clavulanic acid
ZA9511029B (en) Substituted 4-phenylthiazole derivatives process for their preparation and pharmaceutical compositions containing them
IL117629A0 (en) Pharmaceutical compositions containing a benzamide derivative and methods for the preparation thereof
ZA966154B (en) Aminophenylphosphonic acid compounds process for preparing them and pharmaceutical compositions containing them
ZA963350B (en) Cycloheaxane compounds process for their preparation and pharmaceutical compositions containing them
ZA961050B (en) Substituted benzenesulfonylureas and -thioureas processes for their preparation their use for the production of pharmaceutical preparations and pharmaceutical preparations containing them
IL119603A0 (en) Amidinohydrazone derivatives methods for the preparation thereof and pharmaceutical compositions containing the same
ZA9610002B (en) New compounds pharmaceutical preparations containing them and a process for the preparation thereof
AU1066897A (en) Pharmaceutical preparations for oral administration and process for their production
GB2282966B (en) A pharmaceutical composition having anti-decrepit action and a process for preparation thereof